期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 115, 期 1, 页码 128-137出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI200522574
关键词
-
资金
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI043289, P30AI045008] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041864] Funding Source: NIH RePORTER
- NIAID NIH HHS [AI43289, AI45008, P30 AI045008] Funding Source: Medline
- NINDS NIH HHS [R01 NS041864, NS41864] Funding Source: Medline
The persistence of HIV-1 in vitally suppressed infected individuals on highly active antiretroviral therapy (HAART) remains a major therapeutic problem. The use of cytokines has been envisioned as an additional therapeutic strategy to stimulate latent proviruses in these individuals. Immune activation therapy using IL-2 has shown some promise. In the present study, we found that IL-7 was significantly more effective at enhancing HIV-1 proviral reactivation than either IL-2 alone or IL-2 combined with phytohemagglutinin (PHA) in CD8-depleted PBMCs. IL-7 also showed a positive trend for inducing proviral reactivation from resting CD4(+) T lymphocytes from HIV-1-infected patients on suppressive HAART. Moreover, the phylogenetic analyses of viral envelope gp120 genes from induced viruses indicated that distinct proviral quasispecies had been activated by IL-7, as compared with those activated by the PHA/IL-2 treatment. These studies thus demonstrate that different activators of proviral latency may perturb and potentially deplete only selected, specific portions of the proviral archive in vitally suppressed individuals. The known immunomodulatory effects of IL-7 could be combined with its ability to stimulate HIV-1 replication from resting CD4(+) T lymphocytes, in addition to other moieties, to potentially deplete HIV-1 reservoirs and lead to the rational design of immune-antiretroviral approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据